close

From ambition to action: advancing circularity in the pharmaceutical sector

On behalf of the EFPIA Circular Economy Network 

What if the materials used to manufacture medicines could be recycled and reused, rather than becoming waste? Or if pharmaceutical packaging could be designed to use fewer resources? 

As efforts to reduce waste, preserve natural resources and minimise environmental impact gain momentum, the pharmaceutical industry has an important role to play. We recognise that caring for people also means doing our part to care for the planet. This means rethinking how we use resources throughout a medicine's life cycle, while continuing to discover, develop and deliver innovative medicines to patients. 

According to EFPIA's latest member survey, 80% of responding companies now have circular economy targets, up from 60% in 2023, with 75% of reported initiatives having moved beyond the pilot stage. Our latest report brings this progress to life through a non-exhaustive list of real-world examples spanning every stage of a medicine's life cycle.  

White Paper on Circular Economy

Download PDF
Loading the document…
1 / –

From the earliest stages of product design, pharmaceutical companies are exploring ways to use fewer resources, select materials with a lower environmental impact, and develop more sustainable manufacturing processes. UCB, Boehringer Ingelheim, Chiesi, Novartis, and Sanofi are rethinking medicine packaging, from reducing plastic and paper consumption to using more recyclable materials. Johnson & Johnson is developing reusable digital labels for clinical trials. 

Circularity is also about keeping valuable resources in use for longer. Lundbeck is recycling solvents used in manufacturing; Takeda is recycling biomedical plastics that would otherwise end up in landfill, while AstraZeneca is working with partners to turn by-products from renewable energy production into organic fertiliser for local farms. In Denmark, Novo Nordisk, Eli Lilly, Sanofi, Merck, GSK, Novartis and UCB have joined forces through the returpen™ initiative to collect used injection pens, demonstrating what industry-wide collaboration can achieve. EFPIA and its members are also working together to identify and address barriers to the wider adoption of reusable medical devices across Europe, and develop recommendations to support their uptake. 

Public-private partnerships have a crucial role to play too. Initiatives such as DiCE (Digital Health in a Circular Economy) and the Innovative Health Initiative's PHARMECO and ENKORE projects bring together expertise from across sectors to explore more sustainable pharmaceutical manufacturing and circular solutions.  

With the Clean Industrial Deal and the proposed Circular Economy Act setting the EU's direction, we have the opportunity to build on this progress and work with policymakers, regulators and healthcare stakeholders to accelerate the transition towards a more circular economy. 

Circularity does not exist in a regulatory vacuum 

The efforts required to achieve this progress should not be underestimated. Unlike many other products, medicines must meet stringent safety and quality standards throughout their life cycle. Even seemingly simple changes to packaging materials or manufacturing processes can require extensive testing, validation and regulatory approval. 

Our latest member survey highlights these challenges, with Good Manufacturing Practice (GMP) and other regulatory requirements identified as the greatest barriers to implementing circular economy initiatives. For example, solvent recovery has been identified as a key opportunity for decarbonisation, but the lack of consensus with regulators on quality requirements for recovered solvents limits implementation. 

What could help 

  • Coherence: environmental, pharmaceutical and medical technology legislation should work together and avoid contradictory requirements. 
  • Realistic transition periods: timelines to implement new requirements should reflect the time needed to develop, qualify and approve changes to medicines. 
  • Science-based pathways: the use of recycled and secondary raw materials should be enabled through approaches developed with regulators. 
  • Harmonised implementation: requirements should be applied consistently across Member States and supported by investment in recycling infrastructure. 

Looking ahead 

The examples highlighted in our latest report demonstrate the investment and commitment already underway across the pharmaceutical sector to advance circularity. 

We will continue to support these efforts, working with EU institutions, regulators and healthcare stakeholders to develop a framework that supports sustainability while safeguarding patient safety, product quality and access to medicines.